EcoDrugPlus

Opioid Receptor, Kappa 1

Ensembl ID : ENSIPUG00000004228
Gene Symbol: OPRK1
3 Cross references
197 Possible Orthologues:

Opioid Receptor, Mu 1

Ensembl ID : ENSIPUG00000015174
Gene Symbol: OPRM1
4 Cross references
214 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSIPUG00000021946
Gene Symbol: OPRL1
4 Cross references
131 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSIPUG00000023713
Gene Symbol: OXTR
4 Cross references
134 Possible Orthologues:

Oxytocin Receptor A

Ensembl ID : ENSIPUG00000018759
Gene Symbol: OXTRA
3 Cross references
191 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSIPUG00000006617
Gene Symbol: PTH1R
3 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSIPUG00000017034
Gene Symbol: PPARD
4 Cross references
351 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha A

Ensembl ID : ENSIPUG00000014967
Gene Symbol: PPARAA
3 Cross references
383 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha B

Ensembl ID : ENSIPUG00000011666
Gene Symbol: PPARAB
4 Cross references
396 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Delta B

Ensembl ID : ENSIPUG00000000702
Gene Symbol: PPARDB
3 Cross references
392 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Gamma

Ensembl ID : ENSIPUG00000017984
Gene Symbol: LOC108276331
2 Cross references
339 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Gamma

Ensembl ID : ENSIPUG00000011668
Gene Symbol: PPARG
3 Cross references
389 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).